AEON Biopharma Announces Over‑Allotment Sale, Raises ~$1.5M

What Happened
AEON Biopharma, Inc. filed an 8‑K reporting that on July 23, 2026 it issued and sold 4,696,102 shares of its Class A common stock to underwriters following a partial exercise of the underwriters’ over‑allotment option. The shares were sold under the underwriting agreement with Lake Street Capital Markets, LLC; the sale generated approximately $1.5 million in gross proceeds and about $1.4 million in net proceeds after underwriting discounts and commissions. The company previously completed the base offering on July 15, 2026 and noted that the representative had earlier exercised in full the portion of the over‑allotment related to certain two‑year and five‑year milestone warrants covering 6,403,290 shares (or pre‑funded warrants).

Key Details

• 4,696,102 shares of Class A common stock sold on July 23, 2026 via partial over‑allotment exercise.
• Approximately $1.5 million in gross proceeds and about $1.4 million in net proceeds after underwriting fees.
• Underwriting agreement with Lake Street Capital Markets, LLC (Representative).
• Representative had earlier exercised over‑allotment for milestone warrants to purchase 6,403,290 shares or pre‑funded warrants.

Why It Matters

• Cash impact: The transaction provides AEON with roughly $1.4M in net cash, modestly extending its funding runway.
• Dilution: The issuance increases outstanding shares and, together with the exercised milestone warrants, represents additional potential dilution for existing shareholders.
• Corporate context: This is a follow‑on action to the July 15, 2026 offering and reflects underwriter activity (over‑allotment and warrant exercises) rather than operational or management changes. Investors should monitor AEON’s remaining cash, upcoming milestones tied to warrants, and total diluted share count.